Armata Pharmaceuticals
ARMP
53 hedge funds and large institutions have $32.3M invested in Armata Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 17 increasing their positions, 3 reducing their positions, and 11 closing their positions.
467% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 3
73% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 11
18% more funds holding
Funds holding: 45 → 53 (+8)
2.85% more ownership
Funds ownership: 10.72% → 13.57% (+2.9%)
20% less capital invested
Capital invested by funds: $40.2M → $32.3M (-$7.93M)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $10K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$4.54M |
| 2 |
Millennium Management
New York
|
+$1.95M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.43M |
| 4 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$1.12M |
| 5 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
6CM
683 Capital Management
New York
|
-$1.4M |
| 2 |
SEI Investments
Oaks,
Pennsylvania
|
-$760K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$663K |
| 4 |
EI
EAM Investors
Solana Beach,
California
|
-$624K |
| 5 |
Goldman Sachs
New York
|
-$624K |
ARMP Hedge Fund Activity: Q2 2026 in Review
53 of the 8,305 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q2 2026, worth a combined $32.3M — down 20% from $40.2M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new ARMP positions and 11 closed out — a net gain of 8 holders — while 17 added to existing stakes and 3 trimmed.
The largest buyer was BlackRock, adding an estimated $4.54M. The largest seller was 683 Capital Management, exiting entirely with an estimated $1.4M sold.
- 53 institutional investors held Armata Pharmaceuticals (ARMP) as of Q2 2026, up from 45 in Q1 2026.
- Funds reported $32.3M of Armata Pharmaceuticals stock for Q2 2026, down 20% quarter-over-quarter.
- 19 funds opened new Armata Pharmaceuticals positions in Q2 2026 and 11 closed out, a net change of +8 holders.
- The largest Armata Pharmaceuticals buyer in Q2 2026 was BlackRock, an estimated $4.54M added.
- The largest Armata Pharmaceuticals seller in Q2 2026 was 683 Capital Management, an estimated $1.4M sold.
Based on aggregated 13F filings for Q2 2026.